Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

1.

Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.

Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L, Carotenuto A, Tedeschi G, Orefice G, Brescia Morra V.

Neurol Sci. 2013 Apr;34(4):521-8. doi: 10.1007/s10072-012-1088-8. Epub 2012 Apr 22.

PMID:
22526763
[PubMed - indexed for MEDLINE]
2.

Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.

Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.

Acta Neurol Scand. 2012 Nov;126(5):306-14. doi: 10.1111/j.1600-0404.2011.01622.x. Epub 2011 Nov 23.

PMID:
22107083
[PubMed - indexed for MEDLINE]
3.

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.

JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923.

PMID:
23420110
[PubMed - indexed for MEDLINE]
4.

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.

J Neurol Sci. 2012 Dec 15;323(1-2):104-12. doi: 10.1016/j.jns.2012.08.027. Epub 2012 Sep 21.

PMID:
23006974
[PubMed - indexed for MEDLINE]
5.

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.

Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9.

PMID:
19614963
[PubMed - indexed for MEDLINE]
6.

An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.

Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J, Edo MC, Perez-Miralles F, Tur C, Nos C, Huerga E, Comabella M, Rovira A, Montalban X.

Rev Neurol. 2011 Mar 16;52(6):321-30. English, Spanish.

PMID:
21387248
[PubMed - indexed for MEDLINE]
Free Article
7.

Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.

Melis M, Cocco E, Frau J, Lorefice L, Fenu G, Coghe G, Mura M, Marrosu MG.

Neurol Sci. 2014 Mar;35(3):401-8. doi: 10.1007/s10072-013-1527-1. Epub 2013 Aug 30.

PMID:
23990111
[PubMed - indexed for MEDLINE]
8.

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.

Rossi S, Motta C, Studer V, De Chiara V, Barbieri F, Monteleone F, Fornasiero A, Coarelli G, Bernardi G, Cutter G, Stüve O, Salvetti M, Centonze D.

Eur J Neurol. 2013 Jan;20(1):87-94. doi: 10.1111/j.1468-1331.2012.03794.x. Epub 2012 Jun 28.

PMID:
22741530
[PubMed - indexed for MEDLINE]
9.

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.

Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK.

Neurology. 2009 Feb 3;72(5):396-401. doi: 10.1212/01.wnl.0000327341.89587.76. Epub 2008 Nov 5.

PMID:
18987352
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kümpfel T.

J Neurol. 2011 Sep;258(9):1665-9. doi: 10.1007/s00415-011-5996-y. Epub 2011 Mar 23.

PMID:
21431380
[PubMed - indexed for MEDLINE]
11.

Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity.

Bates D, Bartholomé E.

J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):55-60. doi: 10.1136/jnnp-2011-300279. Epub 2011 Aug 23.

PMID:
21865211
[PubMed - indexed for MEDLINE]
12.

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C.

J Neurol. 2013 May;260(5):1388-95. doi: 10.1007/s00415-012-6809-7. Epub 2013 Jan 5.

PMID:
23292204
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

Fernández O, Alvarenga MP, Guerrero M, León A, Alonso A, López-Madrona JC, Leyva L, Oliver B, de Ramón E, Luque G, Fernández V.

Mult Scler. 2011 Feb;17(2):192-7. doi: 10.1177/1352458510385507. Epub 2010 Nov 18.

PMID:
21088044
[PubMed - indexed for MEDLINE]
14.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

PMID:
24898925
[PubMed - indexed for MEDLINE]
15.

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.

Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C.

Mult Scler. 2012 Jan;18(1):64-71. doi: 10.1177/1352458511417481. Epub 2011 Aug 9.

PMID:
21828195
[PubMed - indexed for MEDLINE]
16.

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.

Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1068-74. doi: 10.1136/jnnp-2013-304897. Epub 2013 Apr 19.

PMID:
23606731
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P.

Neurology. 2014 Apr 29;82(17):1491-8. doi: 10.1212/WNL.0000000000000355. Epub 2014 Mar 28.

PMID:
24682966
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

PMID:
19364933
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.

Bonafede MM, Johnson BH, Wenten M, Watson C.

Clin Ther. 2013 Oct;35(10):1501-12. doi: 10.1016/j.clinthera.2013.07.330.

PMID:
24139422
[PubMed - indexed for MEDLINE]
20.

Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.

Kallweit U, Jelcic I, Braun N, Fischer H, Zörner B, Schreiner B, Sokolov AA, Martin R, Weller M, Linnebank M.

Clin Neuropharmacol. 2012 Mar-Apr;35(2):77-80. doi: 10.1097/WNF.0b013e31824644e6.

PMID:
22318192
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk